Page 5 - Daniel Mackey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - March 31, 2021 Message from the CEO IBT is conducting a phase III-study ("The Connection Study") which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing Lactobacillus reuteri as active substance. The active substance is a human bacterial strain found naturally in breast milk. The objective of the study is to show that the active substance can prevent necrotizing enterocolitis (NEC) and improve sustained feeding tolerance. The medical need of a well-func...

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2021, among other things, the following was resolved: adoption of the annual reportthat no dividend is givendischarge

Infant Bacterial Therapeutics Infant Bacterial Therapeutics expands The Connection Study to include infants with a birth weight below 750 grams Infant Bacterial Therapeutics expands The Connection Study to include infants with a birth weight below 750 grams A l ment criteria of The Connection Study to include 500 - 1000 gram birth weight premature infants.   The Data Monitoring Committee (DMC) has performed a per protocol predefined safety and tolerability assessment of the first 300 patients included in the study. The review is now complete and the DMC has no objections to the continuation...

Infant Bacterial Therapeutics AB: Infant Bacterial Therapeutics receives additional patent protection in China Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid bacteria, which protects formulations of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of feeding tolerance in preterm infants. The invention covers a novel way to activate the freez...